Table 1.
Clinical and hematological data and dosage of LCAR-B38M cells in 17 relapsed/refractory multiple myeloma patients
| ID | Sex/age | Subtype | Lesion | Lines of prior therapy | Auto-HSCT | PI* | IMiD† | Clonal BM plasma cells, % | BCMA of plasma cells, % | Serum M protein, g/L | β2-MG, mg/L | LDH, IU/L | HB, g/L | Bone lesions‡ | FLC ratio | FISH | CAR+ T infused, ×106/kg | Peak value of CAR+ T, copy number/μg DNA |
| RJ01 | F/61 | IgG, λ | BM | 5 | Yes | Bortezomib | Lenalidomide | 26.2 | 33.7 | 27.4 | 7.0 | 297 | 69 | No | 0.040 | gain(1q) | 1.40 | 30562 |
| RJ02 | M/57 | IgD, λ | BM, EM§ | 6 | No | Bortezomib | Lenalidomide | 22.1 | 93.2 | 11.5 | 2.4 | 391 | 76 | Yes | 0.040 | gain(1q), del(13q), del(17p), IGH rearrangement¶ | 1.05 | 65925 |
| RJ03 | M/55 | IgG, κ | BM, EM§ | 4 | No | Bortezomib | Lenalidomide | 3.0 | 98.5 | 16.5 | 3.0 | 463 | 91 | Yes | 1.180 | gain(1q) | 1.05 | 16660 |
| RJ04 | M/68 | IgG, κ | BM | 3 | No | Carfilzomib | No | 6.0 | 99.0 | 14.8 | 3.8 | 184 | 81 | No | 24.620 | gain(1q), t (4; 14) | 0.29 | 92918 |
| RJ05 | F/56 | IgG, λ | BM | 3 | No | No | Lenalidomide | 4.5 | 95.0 | 40.2 | 3.7 | 171 | 89 | Yes | 0.050 | gain(1q) | 0.58 | 38428 |
| JS01 | M/67 | IgA, κ | BM, EM§ | 4 | No | Bortezomib | Thalidomid | 0.1 | 88.2 | 11.9 | 4.4 | 153 | 75 | Yes | 4.590 | negative | 0.21 | 2282 |
| JS02 | M/73 | λ | BM | 6 | No | Bortezomib | Lenalidomide/Thalidomid | 4.0 | 99.0 | Negative | 8.0 | 185 | 64 | Yes | 0.003 | del(13q) | 0.28 | 139568 |
| JS03 | M/52 | λ | BM | 3 | Yes | Bortezomib | No | 31.4 | 59.0 | Negative | 5.6 | 397 | 75 | Yes | 0.001 | gain(1q) | 0.57 | 255331 |
| JS04 | F/53 | IgG, κ | BM | 5 | Yes | Bortezomib | Thalidomid | 0.2 | 78.0 | 26.4 | 3.8 | 111 | 115 | Yes | 6.000 | gain(1q), del(13q), t (4; 14) | 0.46 | 83675 |
| JS05 | M/63 | IgA, κ | BM, EM§ | 3 | No | Bortezomib | Lenalidomide/Thalidomid | 0.2 | 78.0 | Trace | 4.2 | 2217 | 88 | Yes | 55.100 | NA | 0.35 | 6306 |
| JS06 | M/56 | IgA, κ | BM, EM§ | 5 | Yes | Bortezomib/Carfilzomib/Ixazomib | Lenalidomide/Pomalidomide | Negative | 95.4 | 7.3 | 3.7 | 194 | 122 | Yes | 15.200 | gain(1q), del(13q) | 1.52 | 225897 |
| JS07 | F/63 | IgA, κ | BM | 11 | Yes | Bortezomib | Lenalidomide | 15.3 | 99.0 | 13.3 | 4.5 | 158 | 83 | No | 4.400 | gain(1q), del(13q) | 1.47 | 5396510 |
| JS08 | M/55 | IgA, κ | BM | 4 | Yes | Bortezomib | Lenalidomide | 30.0 | 99.0 | 17.0 | 3.8 | 128 | 87 | No | 135.100 | gain(1q), t (4; 14) | 0.76 | 1446038 |
| JS09 | M/35 | IgA, κ | BM | 4 | No | Bortezomib | Thalidomid | 80.0 | 98.0 | 15.2 | 3.8 | 244 | 61 | Yes | 2532.200 | Negative | 0.49 | 32830 |
| CZ01 | M/35 | IgG, κ | BM | 3 | Yes | No | Thalidomid | 69.0 | 73.4 | 21.7 | 3.8 | 150 | 60 | Yes | 4.750 | IGH rearrangement¶ | 0.33 | 30861 |
| CZ02 | F/47 | IgG, λ | BM | 6 | Yes | Bortezomib | Lenalidomide/Thalidomid | 22.0 | 95.6 | 64.5 | 2.1 | 280 | 119 | Yes | 82.220 | del(17p) | 0.69 | 664403 |
| CZ03 | F/40 | IgG, λ | BM | 3 | No | Bortezomib | No | 45.0 | 97.7 | 56.0 | 3.2 | 143 | 84 | Yes | NA | gain(1q), del(13q), del(17p), t (4; 14) | 0.35 | NA |
Auto-HSCT, autologous hematopoietic stem cell transplantation; β2-MG, β2-microglobulin; BM, bone marrow; FLC, free light chain; HB, hemoglobin; LDH, lactate dehydrogenase; NA, not available.
Proteasome inhibitors (Bortezomib/Carfilzomib/Ixazomib).
Immunomodulatory drugs (Lenalidomide/Thalidomid/Pomalidomide).
Bone lesions: one or more osteolytic lesions on skeletal radiography, CT, or PET-CT.
Five patients exhibited extramedullary (EM) lesions. RJ02 and JS05 bore plasmacytoma on the forehead; RJ03 presented with extramedullary involvement in the lower jaw, chest skin, and liver; JS01 carried the infiltration lesion on the pleura; and JS06 had tumor infiltration in the pleura and peritoneum.
IGH rearrangement: split FISH signal of IGH without juxtaposing to the common known partner genes (FGFR3, MAF, MAFB, CCND1, CCND3).